Cargando…
PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429454/ http://dx.doi.org/10.1097/01.HS9.0000975796.49668.c2 |
| _version_ | 1785090717267263488 |
|---|---|
| author | Vitolo, Umberto Phillips, Elizabeth H. Alonso, Aránzazu Alonso Merli, Michele Risal, Ashish Namuduri, Manjusha Shen, Biyi Flink, Dina Zhu, Min Mukherjee, Sushmita Brouwer-Visser, Jurriaan Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth Cordoba, Raul |
| author_facet | Vitolo, Umberto Phillips, Elizabeth H. Alonso, Aránzazu Alonso Merli, Michele Risal, Ashish Namuduri, Manjusha Shen, Biyi Flink, Dina Zhu, Min Mukherjee, Sushmita Brouwer-Visser, Jurriaan Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth Cordoba, Raul |
| author_sort | Vitolo, Umberto |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429454 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104294542023-08-17 PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5) Vitolo, Umberto Phillips, Elizabeth H. Alonso, Aránzazu Alonso Merli, Michele Risal, Ashish Namuduri, Manjusha Shen, Biyi Flink, Dina Zhu, Min Mukherjee, Sushmita Brouwer-Visser, Jurriaan Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth Cordoba, Raul Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429454/ http://dx.doi.org/10.1097/01.HS9.0000975796.49668.c2 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Vitolo, Umberto Phillips, Elizabeth H. Alonso, Aránzazu Alonso Merli, Michele Risal, Ashish Namuduri, Manjusha Shen, Biyi Flink, Dina Zhu, Min Mukherjee, Sushmita Brouwer-Visser, Jurriaan Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth Cordoba, Raul PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5) |
| title | PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5) |
| title_full | PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5) |
| title_fullStr | PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5) |
| title_full_unstemmed | PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5) |
| title_short | PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5) |
| title_sort | pb2266: trial in progress: phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory follicular lymphoma and marginal zone lymphoma (olympia-5) |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429454/ http://dx.doi.org/10.1097/01.HS9.0000975796.49668.c2 |
| work_keys_str_mv | AT vitoloumberto pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT phillipselizabethh pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT alonsoaranzazualonso pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT merlimichele pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT risalashish pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT namudurimanjusha pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT shenbiyi pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT flinkdina pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT zhumin pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT mukherjeesushmita pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT brouwervisserjurriaan pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT chaudhryaafia pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT mohamedhesham pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT ambatisrikanth pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 AT cordobaraul pb2266trialinprogressphase3trialofodronextamabpluslenalidomideversusrituximabpluslenalidomideinrelapsedrefractoryfollicularlymphomaandmarginalzonelymphomaolympia5 |